微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > duration of response
duration of response

肿瘤

关键词肿瘤 临床研究术语 临床试验指标

词汇介绍

拓展阅读

解析

Duration   英 //djʊə'reɪʃən/   美 /duˈreɪʃn/

       n. 持续,持续的时间,期间;音长,音延

同根词   durative adj. 持续的,持续性的;durative n. 持续性

       Investment strategies depend on the price of the vaccine, duration of vaccine protection, efficacy, the cost of screening and country resources such as trained professionals and treatment options. 投资战略取决于疫苗价格、疫苗的保护期限、效力、筛查成本以及国家资源,比如训练有素的专业人员和治疗可选方案。

 

Response   英 /rɪ'spɒns/   美 /rɪ'spɑns/

       n. 响应;反应;回答;复数 responses

同根词   responsible adj. 负责的,可靠的;有责任的;respondent adj. 回答的;应答的;responsive adj. 响应的;应答的;回答的;respondent n. [法] 被告;应答者;responsiveness n. 响应能力;有同情心;responder n. 响应器;回答者;responsion n. 答复;应答

       We can do this because of the void response for both the requestor and provider. 我们可以这样做是因为请求者和提供者中的响应都是无效的。

概述

临床试验指标有很多,常见的疗效指标就有 OS、PFS、DOR、ORR、DCR 等,为什么会有那么多指标呢?盲人摸象的故事大家都知道:摸到象牙的觉得大象长得像大萝卜;摸到腿的认为大象像柱子;摸到耳朵的说大象像蒲扇。这个故事讲得是看事物不能片面。反之,如果综合几个人的描述,就有了对大象性形象一个比较全面的了解。药物研发的过程远比摸象还要复杂,目前还没有一个万全的单一评价指标。为了综合评价试验药物的风险和获益,通常一个试验会观察多个类型的指标:衡量疗效(efficacy)的、度量安全性(safet

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis复制标题

Nivolumab治疗晚期非小细胞肺癌患者的4年生存率: 一项汇总分析

发表时间:2019-08-14

影响因子:35.4

作者: Scott J Antonia

期刊:Lancet Oncol.

Given the long duration of responses to PD-1 or PD-L1 inhibitors in patients with previously advanced NSCLC, the association between response and overall survival could be expected to be particularly strong in this setting. However, few studies have explored this question, and the corresponding analyses used were restricted, given that they were based on shorter follow-up durations and smaller study populations than our present analyses. 2-year data from the phase 3 OAK study in patients with previously treated NSCLC showed that response to atezolizumab or docetaxel was associated with increased overall survival, and the benefit of response to atezolizumab was more pronounced; however, no landmark analyses were done and overall survival post-response and post-progression were not evaluated. Landmark analyses were previously used in two of the four studies included in our analyses (CheckMate 063 and 057) to examine the relationship between response and overall survival. A preliminary exploratory landmark analysis from CheckMate 063 based on less than 18 months of follow-up showed that response to nivolumab at 3.5 months (the median time to response) was associated with increased overall survival versus stable disease or progressive disease.

译文

鉴于先前晚期NSCLC患者对PD-1或PD-L1抑制剂的反应持续时间较长,因此在这种情况下,反应和总体生存之间的关联可能会特别强烈。然而,很少有研究探索过这个问题,并且所使用的相应分析受到限制,因为它们基于较短的随访时间和较小的研究人群而不是我们目前的分析。来自先前治疗的NSCLC患者的3期OAK研究的2年数据显示,对atezolizumab或多西紫杉醇的反应与总生存期增加有关,对atezolizumab反应的益处更为明显;然而,没有进行具有里程碑意义的分析,并且没有评估总体存活后响应和后进展。先前在我们的分析(CheckMate 063和057)中包括的四项研究中的两项中使用了标志性分析来检查反应与总体存活之间的关系。 CheckMate 063基于不到18个月的随访进行的初步探索性里程碑分析显示,3.5个月时对nivolumab的反应(中位反应时间)与稳定疾病或进展性疾病的总体存活率增加有关。